Oxygen-dependent regulation of pulmonary circulation.

[1]  Kai-Uwe Eckardt,et al.  The FASEB Journal express article 10.1096/fj.02-0445fje. Published online December 17, 2002. Widespread, hypoxia-inducible expression of HIF-2α in distinct cell populations of different organs , 2022 .

[2]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[3]  G. Berry,et al.  Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. , 2002, American journal of respiratory and critical care medicine.

[4]  M. Humbert,et al.  Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension , 2002, Nature Medicine.

[5]  G. Semenza.  Signal transduction to hypoxia-inducible factor 1. , 2002, Biochemical pharmacology.

[6]  G. Haddad,et al.  Regulation of TGF-beta ligand and receptor expression in neonatal rat lungs exposed to chronic hypoxia. , 2002, Journal of applied physiology.

[7]  N. Voelkel,et al.  Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[8]  E. Gabrielson,et al.  Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. , 2002, Cancer research.

[9]  M. Xiong,et al.  A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patients. , 2002, Rheumatology.

[10]  L. Nelin,et al.  Developmental differences in pulmonary eNOS expression in response to chronic hypoxia in the rat. , 2002, Journal of applied physiology.

[11]  Till Acker,et al.  Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice , 2002, Nature Medicine.

[12]  Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.

[13]  L. Magder,et al.  Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. , 2002, Clinical immunology.

[14]  Yusuke Nakamura,et al.  An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. , 2002, Cancer research.

[15]  A. Zaiman,et al.  Prostacyclin analogs as the brakes for pulmonary artery smooth muscle cell proliferation: is it sufficient to treat severe pulmonary hypertension? , 2002, American journal of respiratory cell and molecular biology.

[16]  M. Husain,et al.  Overexpression of the Serine Elastase Inhibitor Elafin Protects Transgenic Mice From Hypoxic Pulmonary Hypertension , 2002, Circulation.

[17]  K. Tyler,et al.  TRAIL and inhibitors of apoptosis are opposing determinants for NF-κB-dependent, genotoxin-induced apoptosis of cancer cells , 2002, Oncogene.

[18]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Humbert,et al.  Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. , 2001, The Journal of clinical investigation.

[20]  G. Semenza,et al.  Expression of angiogenesis‐related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis , 2001, The Journal of pathology.

[21]  Lawrence Hunter,et al.  GEST: a gene expression search tool based on a novel Bayesian similarity metric , 2001, ISMB.

[22]  M. Ringnér,et al.  Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks , 2001, Nature Medicine.

[23]  N. Voelkel,et al.  Genomic approaches to research in pulmonary hypertension , 2001, Respiratory research.

[24]  K. Webster,et al.  Molecular Regulation of the Endothelin-1 Gene by Hypoxia , 2001, The Journal of Biological Chemistry.

[25]  N. Voelkel,et al.  Gene Expression Patterns in the Lungs of Patients With Primary Pulmonary Hypertension: A Gene Microarray Analysis , 2001, Circulation research.

[26]  G. Miller,et al.  HOX genes in human lung: altered expression in primary pulmonary hypertension and emphysema. , 2001, The American journal of pathology.

[27]  P. Hirth,et al.  Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  P. Hirth,et al.  Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. , 2000, The Journal of clinical investigation.

[29]  S. Eddahibi,et al.  Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. , 2000, American journal of respiratory cell and molecular biology.

[30]  N. Voelkel,et al.  Hypoxia-induced pulmonary vascular remodeling: a model for what human disease? , 2000, The Journal of clinical investigation.

[31]  M. d’Ortho,et al.  Inhibition of Matrix Metalloproteinases by Lung TIMP-1 Gene Transfer or Doxycycline Aggravates Pulmonary Hypertension in Rats , 2000, Circulation research.

[32]  N. Sampas,et al.  Molecular classification of cutaneous malignant melanoma by gene expression profiling , 2000, Nature.

[33]  E. Winzeler,et al.  Genomics, gene expression and DNA arrays , 2000, Nature.

[34]  K. Lesch,et al.  Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. , 2000, The Journal of clinical investigation.

[35]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[36]  K. Harada,et al.  Physiologic significance of nitric oxide and endothelin‐1 in circulatory adaptation , 2000, Pediatrics international : official journal of the Japan Pediatric Society.

[37]  N. Voelkel,et al.  Severe pulmonary hypertensive diseases: a perspective. , 1999, The European respiratory journal.

[38]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[39]  W. Rumsey,et al.  ZD1611, an orally active endothelin-A receptor antagonist, prevents chronic hypoxia-induced pulmonary hypertension in the rat. , 1999, Pulmonary pharmacology & therapeutics.

[40]  N. Voelkel,et al.  Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. , 1999, The Journal of clinical investigation.

[41]  N. Voelkel,et al.  cGMP and cAMP cause pulmonary vasoconstriction in the presence of hemolysate. , 1999, Journal of applied physiology.

[42]  C K Breuer,et al.  Tissue-engineered heart valves. Autologous valve leaflet replacement study in a lamb model. , 1996, Circulation.

[43]  B. Koller,et al.  Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. , 1996, The Journal of clinical investigation.

[44]  Haworth Sg.  Development of the normal and hypertensive pulmonary vasculature. , 1995 .

[45]  J. Launay,et al.  Increased plasma serotonin in primary pulmonary hypertension. , 1995, The American journal of medicine.

[46]  N. Voelkel,et al.  Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. , 1995, The Journal of clinical investigation.

[47]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[48]  N. Voelkel,et al.  PAF antagonists inhibit pulmonary vascular remodeling induced by hypobaric hypoxia in rats. , 1992, Journal of applied physiology.

[49]  N. Voelkel,et al.  Isolated perfused rat lung in arachidonate studies. , 1990, Methods in enzymology.

[50]  P. Fiorini,et al.  Dark J‐V characteristic of p‐i‐n a‐Si:H solar cells , 1989 .

[51]  N. Voelkel,et al.  Importance of vasoconstriction in lipid mediator-induced pulmonary edema. , 1989, Journal of applied physiology.

[52]  T. Higenbottam,et al.  LONG-TERM TREATMENT OF PRIMARY PULMONARY HYPERTENSION WITH CONTINUOUS INTRAVENOUS EPOPROSTENOL (PROSTACYCLIN) , 1984, The Lancet.

[53]  A Kahn,et al.  Interstitial lung disease. , 1982, The Journal of the Arkansas Medical Society.

[54]  N. Voelkel,et al.  Moderation of hypoxic vasoconstriction by infused arachidonic acid: role of PGI2. , 1980, Journal of applied physiology: respiratory, environmental and exercise physiology.

[55]  C. Wagenvoort,et al.  Pathology of pulmonary hypertension , 1977 .

[56]  A. Davidson,et al.  Inhibition of Hypoxic Pulmonary Vasoconstriction by Calcium Antagonists in Isolated Rat Lungs , 1976, Circulation research.

[57]  A. Hauge,et al.  Conditions governing the pressor response to ventilation hypoxia in isolated perfused rat lungs. , 1968, Acta physiologica Scandinavica.

[58]  K. Vonkaulla.  LIVER IN REGULATION OF FIBRINOLYTIC ACTIVITY. , 1964, Lancet.